Detalhe da pesquisa
1.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
N Engl J Med
; 387(25): 2331-2343, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546625
2.
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
N Engl J Med
; 387(9): 810-823, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053506
3.
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med
; 382(10): 893-902, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130813
4.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Antimicrob Agents Chemother
; 66(3): e0199121, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007139
5.
Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Antimicrob Agents Chemother
; 63(11)2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31451504
6.
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
BMC Pulm Med
; 19(1): 152, 2019 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31412895
7.
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
BMC Infect Dis
; 18(1): 317, 2018 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29996783
8.
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"
Antimicrob Agents Chemother
; 66(4): e0022322, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323014
9.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Lancet
; 385(9979): 1738-1747, 2015 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795076
10.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Lancet Respir Med
; 12(2): 117-128, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980911
11.
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Lancet
; 380(9846): 986-93, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22828481
12.
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Antimicrob Agents Chemother
; 56(6): 3027-31, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22430968
13.
Tuberculosis and antimicrobial resistance - new models of research and development needed.
Bull World Health Organ
; 95(5): 315, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28479629
14.
Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.
PLoS Med
; 13(3): e1001965, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933883
15.
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
BMJ Open
; 11(12): e051521, 2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862287
16.
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Antimicrob Agents Chemother
; 54(8): 3402-7, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20498324
17.
Current development and future prospects in chemotherapy of tuberculosis.
Respirology
; 15(5): 764-78, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20546189
18.
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.
Antimicrob Agents Chemother
; 53(9): 3720-5, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19528280
19.
Challenges in tuberculosis drug research and development.
Nat Med
; 13(3): 290-4, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17342142
20.
Analysis of the clinical antibacterial and antituberculosis pipeline.
Lancet Infect Dis
; 19(2): e40-e50, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30337260